Effect of Tamoxifen on Breast Tissue Density in Premenopausal Breast Cancer

Breast Journal

Volumn 10, Issue 1, 2004, Pages 27-32

  Slanetz, Priscilla J ^a   Grandpre, Lauren E ^a   Yeh, Eren D ^b   Kopans, Daniel B ^b   Mendel, Jeffrey B ^a  

^a ST ELIZABETH'S MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adjuvant treatment; Breast cancer; Chemoprevention; Mammographic density; Selective estrogen receptor modulator (SERM); Tamoxifen

Indexed keywords

SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CASE REPORT; DRUG EFFECT; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAMMOGRAPHY; PREMENOPAUSE;

ADULT; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; MAMMOGRAPHY; PREMENOPAUSE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 0742288165     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2004.09606.x     Document Type: Article

References (25)

1. Lippman ME, Krueger KA, Eckert S, et al. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene in multiple outcomes of raloxifene evaluation study participants. J Clin Oncol 2001;19:3111-16.
2. Kelsey JL, Bernstein L. Epidemiology and prevention of breast cancer. Annu Rev Public Health 1996;17:47-67.
3. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
4. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-88.
5. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 1998;352:98-101.
6. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomized women. Lancet 1994;352:93-97.
7. Benhaim DI, Lopchinsky R, Tartter PI. Lumpectomy with tamoxifen as primary treatment for elderly women with early-stage breast cancer. Am J Surg 2000;180:162-66.
8. Berkowitz JE, Gatewood OM, Goldblum LE, Gayler BW. Hormonal replacement therapy: mammographic manifestations. Radiology 1990;174:199-201.
9. Stomper PC, Van Voorhis BJ, Ravnikar VA, Meyer JE. Mammographic changes associated with postmenopausal hormone replacement therapy: a longitudinal study. Radiology 1990;174:487-90.
10. Laya MB, Gallagher JC, Schreiman JS, et al. Effect of postmenopausal hormonal replacement therapy on mammographic density and parenchymal pattern. Radiology 1995;196:433-37.
11. Marugg RC, van der Mooren MJ, Hendriks JH, et al. Mammographic changes in postmenopausal women on hormonal replacement therapy. Eur Radiol 1997;7:749-55.
12. Brisson J, Brisson B, Cote G, et al. Tamoxifen and mammographic densities. Cancer Epidemiol Biomarkers Prev 2000;9:911-15.
13. Atkinson C, Warren R, Bingham SA, Day NE. Mammographic patterns is a predictive biomarker of breast cancer risk: effect of tamoxifen. Cancer Epidemiol Biomarkers Prev 1999;8:863-66.
14. Son HJ, Oh KK. Significance of follow-up mammography in estimating the effect of tamoxifen in breast cancer patients who have undergone surgery. AJR Am J Roentgenol 1999;173:905-9.
15. Taylor C, Georgian-Smith D. Regression of breast cancer in four patients treated with tamoxifen: mammographic features. AJR Am J Roentgenol 1994;162:613-16.
16. Ricciardi I, Ianniruberto A. Tamoxifen-induced regression of benign breast lesions. Obstet Gynecol 1979;54:80-84.
17. Hurst JL, Mega JF, Hogg JP. Tamoxifen-induced regression of breast cysts. Clin Imaging 1998;22:95-98.
18. Byrne C. Studying mammographic density: implications for understanding breast cancer. J Natl Cancer Inst 1997;89:531-33.
19. Feig S. Hormonal reduction of mammographic densities: potential effects on breast cancer risk and performance of diagnostic and screening mammography. J Natl Cancer Inst 1994;86:408-9.
20. Spicer DV, Ursin G, Parisky YR, et al. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst 1994;86:431-36.
21. Oza AM, Boyd NF. Mammographic parenchymal patterns: a market of breast cancer risk. Epidemiol Rev 1993;15:196-208.
22. Cummings SR, Eckert S, Krueger K, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 1999;281:2189-97.
23. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 2001;65:125-34.
24. Christodoulakos GE, Lambrinoudaki IV, Vourtsi AD, et al. Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study. Menopause 2002;9:110-16.
25. Jackson VP, San Martin JA, Secrest RJ, et al. Comparison of the effects of raloxifene and continuous-combined hormone therapy on mammographic breast density and breast tenderness in postmenopausal women. Am J Obstet Gynecol 2003;188:389-94.